This content is intended for healthcare professionals in Brazil, France, Germany and Spain only.

Please confirm that you are a healthcare professional in one of those countries.

Decline

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Listen on the go
CORRECT!
Next question
Faculty & Disclosures
Dr Antonio Llombart-Cussac

Hospital Arnau de Vilanova, Valencia, Spain

Medical doctor and specialist in medical oncology. He is currently head of the Medical Oncology Service at the Arnau de Vilanova Hospital in Valencia and full professor of Clinical Oncology at the CEU – Cardenal Herrera University

With more than 5 years of academic and research training in France and the United States, he is an international expert in breast cancer, with more than 100 indexed publications in the last 5 years. Involved in different Breast Cancer research groups, he is a founding partner and senior-expert at MedSIR, a company dedicated to promoting high-impact clinical research in collaboration with the scientific community, pharmaceutical and biotech companies.

He has been scientific coordinator (2006-2010) and past-president (2010-2014) of the SOLTI Research Group. He is a member of different scientific societies (SEOM, ESMO, ASCO, AACR, ECO). Since 2017 he is a reference academician of the Royal Academy of Medicine and Sciences of the Valencian Community.

Dr Antonio Llombart-Cussac discloses: Research support from Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp&Dhome, Gilead, Daiichi Sankyo. Consulting/advisor for Lilly, Roche, Pfizer, Novartis. Speaker’s Bureaus for Lilly, Astrazeneca, Merck Sharp&Dhome, Pfizer, Novartis. Travel support from Roche, Pfizer, Astrazeneca, Steamline therapeutics, Merck Sharp&Dhome. Patents Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED. Stock or other ownership MAJ3 Capital & Initia-Research.

Dr Alessandra Morelle

Oncoclínicas Porto Alegre, Brazil

Dr Morelle is an oncologist, with a PhD in Internal Medicine from PUCRS, specializing in the treatment of breast cancer and gynecological tumors. Co-founder of Thummi, a digital support platform for cancer patients, launched in 2018, she integrates technology and innovation to improve health care. She is the creator and instructor of the online course “I have cancer, now what?”, in addition to offering personalized medical follow-up for patients undergoing chemotherapy.​

She works in the organization and curatorship of the Future & Innovation Health Forum, an event that promotes discussions about the future of health and technological innovation in the sector. She actively participates in initiatives aimed at personalized medicine, shared decision-making, and new technological approaches to cancer care.​

Dr Alessandra Morelle discloses: Lectures and educational activities from Astrazeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer, Lilly, Libbs. Advisory board and/or Expert Input Forum from Astrazeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer. Principal investigator of sponsored clinical research studies for Astra Zeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer. Principal investigator of investigator-initiated studies for Astra Zeneca, MSD, Novartis, Gilead, Daiichi Sankyo, Roche, Pfizer.

Dr Tal Sella

Sheba Medical Center, Ramat Gan, Israel

Dr Sella earned his medical degree from Tel Aviv University’s Sackler School of Medicine and trained in medical oncology at Sheba Medical Center, focusing on breast cancer treatment. In 2018, he joined Dana Farber Cancer Institute as a Goldfarb and Rudkin Family international fellow in breast oncology, where he initiated research projects within the Young Women with Breast Cancer Study under the mentorship of Ann Partridge, MD, MPH.​

​In 2022, Dr. Sella returned to Sheba Medical Center, heading the Service for Young Women with Breast Cancer and serving as the medical director of the Oncology Clinical Trials Department. His research focuses on treatment and survivorship of premenopausal and young women with breast cancer, including genetics, fertility, quality of life, adherence, decision-making, and treatment optimization.​

Dr Tal Sella discloses: Honoraria from Roche, Eli Lilly, Novartis, MSD, Gilead, Astrazeneca and Stemline. Advisory from Novartis. Travel support from Roche, Gilead, Oncotest, Pfizer and Astra-Zeneca.

Prof. Huiping Li

Peking University Cancer Hospital and Institute, Beijing, China

Prof. Li is the Director of the Department of Breast Medical Oncology at Beijing Cancer Hospital, serving as Chief Physician and Doctoral Supervisor, Chairman of the Breast Disease Research Center of China Medical Women’s Association, and Vice Chairman of its Clinical Oncology Committee. Prof. Li is an evaluation expert for key projects of the Ministry of Science and Technology and the National Natural Science Foundation, and contributes to the NCCN breast cancer guidelines and Chinese medicine treatment guidelines for advanced breast cancer.​

​She has published numerous papers as first author and corresponding author, including MONARCH plus, and leads significant clinical research projects, such as the study of Fluzoparib±Apatinib in HER2-negative metastatic breast cancer patients with germline BRCA mutation.​

Prof. Huiping Li discloses: Prof Huiping Li will attend this meeting as a panelist on behalf of Eli Lilly China. For the purpose of transparency, it is hereby disclosed that the speaker may have had or currently have the following cooperative relationships, including but not limited to: employees, contract representatives, shareholders, consultants, researchers, investors, etc.

Back to Faculty
touchONCOLOGY touchONCOLOGY
 
Invitation to an upcoming Educational Meeting

touchFEATURE

CDK4/6 inhibitors in HR+ HER2- EBC: Expert discussions on patient identification, efficacy, and adherence

Join the event live on Thursday 10 April 2025 with international experts Dr Antonio Llombart-Cussac, Dr Alessandra Morelle, Dr Tal Sella, and Prof. Huiping Li (Session 1 only).

To register, please click on the relevant Session below.

Session 1: 10th April 13:00-14:00 CEST (external site):

Session 2: 10th April 17:00-18:00 CEST (external site):

This is an international event, intended for HCPs only.

Agenda

Learning Objectives
After attending the Educational Meeting, participants should better be able to:

  • Evaluate the risk of recurrence in patients with HR+ HER2- EBC
  • Discuss individualized treatment plans with example patients cases
  • Explore strategies to maximize clinical outcomes by supporting adherence

Attendees are invited to share thoughts, perspectives, and questions with the international team of breast cancer experts via the ON24 Webinar platform.

Live translations will be provided during the event in the following languages: Spanish, French, German and Portuguese (Brazilian).

Useful tips

  • To register for the event, go to Registration.

Topics covered in this activity

Breast Cancer
This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

No endorsement by Eli Lilly or TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

GM-55294; PP-AL-ES-1312; PP-AL-FR-0871; PP-AL-DE-2904
Date of preparation: March 2025

Material destinado exclusivamente a profissionais prescritores de medicamentos.
VV-MED-170513. Março/2025

Useful tips

  • To register for the event, go to Registration.

Topics covered in this activity

Breast Cancer
Feedback

Thank you! We really appreciate you taking time to give us your feedback on this activity.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup